最高检经济犯罪检察厅（知识产权检察厅）副厅长刘太宗介绍，本次发布的典型案例涉及领域广 泛、类型多样，涵盖先进制造业、软件算法等高新技术领域，网络文学、非物质文化遗产等文化领域， 以及中医药等重点民生领域。 在"北京君某科技有限公司、孙某明、胡某伟等四人侵犯商业秘密案"中，检察机关同步审查刑事犯 罪与民事侵权事实，从关联的在先民事判决中审查发现遗漏侵犯经营信息犯罪线索，综合全案证据予以 追诉。 在"宁波声某文化传媒有限公司著作权侵权纠纷系列虚假诉讼监督案"中，检察机关强化虚假诉讼监 督，一体履行知识产权刑事检察、民事检察职能，监督纠正错误民事裁判，依法移送犯罪线索，被告人 被判处刑罚。 最高人民检察院日前发布9件检察机关知识产权保护典型案例，展现知识产权检察综合履职的工作 成效。 刘太宗表示，发布这一批典型案例意在更加全面、直观地展现知识产权检察工作，引领知识产权检 察案件的专业化、规范化办理，提升全社会知识产权保护意识，着力营造"尊重知识、崇尚创新、诚信 守法、公平竞争"的良好氛围。（记者 刘硕、朱高祥） 此次发布的"张某、孙某侵犯著作权案"是数字版权领域新类型案件，涉案作品众多、金额特别巨 大，检察机关精准 ...

Core Insights - A consumption trend focused on "blood nourishment" is emerging, driven primarily by young women aged 20-29, who are increasingly engaging with this market through social media platforms like Xiaohongshu and Douyin, generating billions of views and millions of discussions [1][3] Market Dynamics - The demand for blood nourishment has evolved from a functional supplement to a lifestyle ritual, leading to a diverse product matrix and innovative projects that cater to this demographic's needs [3][5] - Traditional products are being replaced by modern, aesthetically appealing alternatives, as young women prefer convenient and culturally enriched options over traditional remedies [4][5] Industry Transformation - The industry is witnessing a shift as traditional medicine companies adapt to the preferences of younger consumers, with products like "night recovery drinks" and "collagen peptide beverages" gaining popularity [5][6] - Data indicates a slow decline in overall sales in the blood nourishment market, with a projected revenue of approximately 25.85 billion yuan in 2024, down about 4% year-on-year, while specific products like donkey-hide gelatin are seeing significant growth, with some experiencing nearly 50% year-on-year increases [6] Brand Strategies - Brands are increasingly focusing on emotional value and lifestyle integration, moving away from traditional narratives to resonate with younger consumers [9][10] - Companies like Yunnan Baiyao are leveraging social media to connect with young women by addressing common health concerns and creating relatable content [10][11] Product Innovation - Brands are innovating by creating products that fit seamlessly into the daily lives of young women, such as instant herbal powders and health snacks, while also exploring cross-industry collaborations [15][16] - New entrants like Minayo are targeting the blood nourishment market with clinically validated products, emphasizing convenience and taste to appeal to younger consumers [21][22] Market Opportunities - The market for blood nourishment products is expanding, with a growing number of companies entering the space, highlighting the importance of attracting young consumers [19][23] - The health and wellness sector is showing resilience, with significant opportunities for companies to explore niche demands within the broader health market [23]

Core Viewpoint - The development of traditional Chinese medicine (TCM) in Donglan County is being positioned as a key driver for rural revitalization, leveraging ecological planting and deep processing to create a comprehensive industry chain [7][9]. Group 1: Agricultural Practices and Economic Impact - The introduction of tissue culture and semi-wild planting methods has increased the yield of the herb "Yao Huang Lian" from 30 kg to 200 kg per mu, with over 5,000 mu of planting area established in the county [3][7]. - The "medicine-grain intercropping" model allows farmers to plant rice after harvesting Yao Huang Lian, leading to multiple harvests from the same land [3][7]. - The economic benefits of these practices are significant, with Yao Huang Lian yielding 500 kg per mu and generating a value of 25,000 yuan, while other herbs like "Shan Wu Gui" can yield 5,000 kg per mu with a value of 50,000 yuan [3][7]. Group 2: Industry Development and Government Support - Donglan County has established a comprehensive TCM industry chain with a total planting area of 171,800 mu and an annual output of over 6,500 tons of medicinal materials [7][8]. - The county government has created the Donglan County TCM Development Center to coordinate and promote industry growth, with an annual budget of over 50 million yuan for infrastructure improvements [8]. - The leading pharmaceutical company, Guangxi Hefeng Pharmaceutical, has adopted a "company + base + cooperative + farmer" model, achieving a production value of 400 million yuan in 2024 [8][9]. Group 3: Cultural and Tourism Integration - The integration of TCM with tourism has led to the development of unique experiences such as medicinal cuisine and health teas, generating over 10 million yuan in revenue [9][10]. - Donglan County plans to enhance its TCM brand by establishing demonstration bases and promoting geographical indication trademarks, aiming to attract more tourists and increase economic output [10]. - In the first quarter of 2025, the county received 867,100 tourists, with TCM health tourism accounting for over 45% of total consumption [10].

Group 1 - The Chengdu Traditional Chinese Medicine (TCM) Industry Circle Strengthening Conference was held on April 29, 2025, focusing on the theme of "integrated empowerment for efficiency enhancement and shared quality development" [1] - The updated Chengdu TCM Industry Support Policy List (version 2.0) was released, which aims to promote collaborative and shared development of the TCM industry ecosystem [3] - Chengdu has established itself as a significant hub for TCM, with 3,394 TCM medical institutions and 126 large-scale enterprises, achieving an industry scale exceeding 30 billion yuan [3] Group 2 - The new policy list emphasizes comprehensive coverage of the entire TCM industry chain, addressing pain points for enterprises, and enhancing technological integration [3] - A long-term collaborative mechanism with Hong Kong, Macau, and Taiwan was initiated to promote TCM internationalization, focusing on standard recognition and resource sharing [5] - A total of 65 supply-demand items were identified, covering areas such as medicinal material cultivation, technology research and development, and medical cooperation [5] Group 3 - The conference featured a roadshow segment to facilitate direct information exchange between enterprises and promote collaboration in TCM technology innovation [6] - Future initiatives will include building precise platforms, strengthening policy support, and facilitating international market access for TCM enterprises [8] - A signing ceremony was held for 20 enterprises across various fields, including TCM manufacturing, research, and health care [9]

走进实验室，映入眼帘的既有中药煎壶、捣药罐等传统容器还有药物递送模拟器、胶囊填充机等设备。 近年来，实验室也在探索重点交叉学科研究领域，其中就包括中药+人工智能(AI)。澳门大学中华医药 研究院副院长路嘉宏表示，要推进中药高质量发展，离不开中药与先进技术的结合。 "过去我们进行百万计的小分子筛选可能需要十年时间。在引入人工智能技术替代人工筛选后，数十秒 就完成了同样工作，研究院所使用的人工智能技术正是与内地的一家企业合作的。"路嘉宏说。 28日下午，"机遇湾区""机遇香港""机遇澳门"采访团来到中药质量研究国家重点实验室(澳门大学)。 过去数年，实验室取得了多项重大突破，建立了中药化学、质量分析、生物活性质量监督、安全质量检 定、中药制药和中药质量评价等六个具有国际水平的关键技术平台。陈新说："我们希望通过高质量的 中医药科学研究和成果转化，为人类的健康和福祉作出贡献。"(经济日报记者陈蓉蓉常理) 中药质量研究国家重点实验室(澳门大学)于2010年正式成立，是国家首个中医药领域的国家重点实验 室。多年来以中药质量为核心科学问题，推动中医药标准化、国际化和现代化。实验室以中药质量的评 价为研究方向，以中医药创新 ...

国医大师、全国中医药高校教学名师李佃贵作报告。 岐黄学者、河北省中西医结合医药研究院院长贾振华致辞。 国医大师、全国中医药高校教学名师李佃贵以《凝聚燕赵中医，助力健康中国》为题作报告。他指出， 燕赵中医文化历史悠久、源远流长，曾涌现出许多影响深远的名医大家，为我国中医药的发展作出了不 可磨灭的贡献。做好中医传承工作的前提是，必须充分认识中医和中医文化，充分认识到中医文化全 面、系统、完整地保有中华文明的核心理念。 4月25日，首届燕赵医学传承发展大会2025年京津冀燕赵医学研究中心学术年会暨第十二届燕赵医学讲 坛在石家庄以岭健康城召开。 中华中医药学会副会长王国辰强调，传承发展燕赵医家医学人文思想，能够更好地实现燕赵医学理论、 实践与医学人文思想的融合传承，提升中医药院校学生的人文素养，并在医疗实践过程中营造良好的人 际关系，在医疗机构中打造和谐的文化氛围。 河北省中医药管理局局长张凯指出，全面发展燕赵医学是加快中医药现代化发展，是推动京津冀协同发 展战略实施的重要举措。 岐黄学者、河北省中西医结合医药研究院院长贾振华提出，发展燕赵医学既要进行理论学术思想挖掘整 理，又要进行处方特色制剂的开发。 河北省中药材 ...

Group 1 - The Macao SAR government aims to promote integrated development in education, technology, and talent, focusing on creating a high-end talent hub [1] - The government plans to adjust higher education disciplines and optimize the transformation of scientific research achievements based on national and Macao development needs [1] - A third talent introduction plan will be launched after evaluating the effectiveness of the previous two plans [1] Group 2 - The government intends to strengthen ties with universities in Portuguese-speaking countries, countries along the Belt and Road, and Southeast Asia to attract international students [1] - There will be initiatives to support youth employment in the Greater Bay Area and increase internship opportunities in designated enterprises in mainland China [1] - The development of the traditional Chinese medicine health industry and cultural and sports industries is prioritized to position Macao as a key open gateway and a window for cultural exchange [2] Group 3 - The construction of the Macao University in the Hengqin Guangdong-Macao Deep Cooperation Zone will be phased, with plans to extend more universities to the cooperation zone [2] - Coordination between Macao and Hengqin in research, education, and talent development will be enhanced [2]

Investment Rating - The report maintains a positive investment rating for the pharmaceutical industry, focusing on innovation and growth opportunities in various segments [4]. Core Insights - The pharmaceutical sector is experiencing a comprehensive recovery, with a focus on innovative drug development, particularly in oncology, autoimmune diseases, GLP-1, stem cell therapy, and gene therapy [1][2]. - The report highlights the importance of domestic innovation in pharmaceuticals, with significant attention on the upcoming AACR and ASCO conferences, where numerous Chinese companies are expected to present their research [2][13]. - The report emphasizes the potential for growth in the CXO sector due to recovering domestic demand and stable overseas demand, suggesting a valuation recovery for leading companies [8]. - The report identifies key companies to watch, including 恒瑞医药, 百济神州, and others across various segments such as innovative drugs, medical devices, and IVD [3]. Summary by Sections Innovative Drugs - The report notes the approval of 康方依沃西单抗 for first-line treatment of PD-L1 positive NSCLC, showing a 22.3% reduction in mortality risk [2]. - It highlights the upcoming AACR conference with over 120 Chinese pharmaceutical companies presenting nearly 300 new drug research results [13]. CXO Sector - The CXO sector is expected to benefit from supportive policies and a reduction in geopolitical risks, leading to a potential valuation uplift [8]. Traditional Chinese Medicine - The report suggests monitoring companies related to pediatric medications, such as 济川药业 and 葵花药业, due to their relevance to fertility subsidies [2]. Blood Products - The report emphasizes the growth potential in the immunoglobulin market over the next 3-5 years, driven by increased demand and pricing improvements [2][25]. Vaccines - The vaccine sector is under pressure, but there are opportunities in HPV vaccines and other high-value products [27]. Upstream Supply Chain - The report recommends focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [30]. IVD Sector - The report indicates that the IVD industry is poised for growth due to the implementation of centralized procurement policies and increasing domestic demand [33]. Medical Devices - The report highlights the potential for growth in the CGM market, particularly with the FDA approval of related products [38]. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [44]. Offline Pharmacies - The report notes that the pharmacy sector is stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [46]. Raw Materials - The report discusses the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [50]. Innovative Devices - The report emphasizes the potential for AI applications in medical devices, particularly in surgical navigation and pathology screening [53]. Instrumentation - The report anticipates a recovery in the scientific instrumentation sector, driven by increased domestic demand and new product launches [57].

Investment Rating - The report maintains a positive investment rating for the pharmaceutical industry, highlighting a recovery and focus on innovation [4]. Core Views - The pharmaceutical sector is experiencing a sustained recovery in fundamentals, supported by favorable policies, with a focus on innovative drug growth, particularly in areas such as oncology, autoimmune diseases, GLP-1, stem cell therapy, and gene therapy [1][2]. - The report emphasizes the importance of domestic pharmaceutical substitution and the growth of medical consumption, especially in aesthetic medicine [1]. Summary by Sections Innovative Drugs - The AACR conference is ongoing, with significant participation from over 120 Chinese pharmaceutical companies presenting nearly 300 new drug research results [11]. - Key approvals include the domestic approval of 康方依沃西单抗 for PD-L1 positive NSCLC and the FDA approval of 派安普利单抗 for nasopharyngeal carcinoma [2][72]. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive policies for innovative drug development and a reduction in geopolitical risks [6]. Traditional Chinese Medicine - The SW secondary index for traditional Chinese medicine has underperformed compared to the broader market, indicating challenges in this segment [19]. Blood Products - The report highlights the increasing demand for immunoglobulin products and the potential for price improvements in the blood products sector, particularly for companies like 天坛生物 and 派林生物 [23]. Vaccines - The vaccine sector is facing challenges due to low birth rates, but there is potential for growth in HPV vaccines and other areas [25]. Upstream Supply Chain - The report suggests focusing on companies with strong brand and operational capabilities in the chemical and biological reagent sectors [28]. IVD (In Vitro Diagnostics) - The IVD industry is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic substitution [31]. Medical Devices - The report recommends attention to the CGM market, particularly products from 三诺生物, as they align with the growth of GLP-1 drugs [36]. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [43]. Offline Pharmacies - The offline pharmacy sector is stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies like 华海药业 and 海正药业 [49]. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [52]. Instrument Equipment - The scientific instrument sector is expected to recover as demand improves, with a focus on companies enhancing their market presence through new product launches [57]. Low-value Consumables - The report notes a potential recovery in the low-value consumables sector, particularly for companies like 采纳股份 and 美好医疗 [60].

香港卫生署署长林文健医生指出："特区政府感谢中央政府的批准和国家药监局的支持，把简化港澳注 册中成药注册审批安排由外用药油扩展至口服中成药。卫生署一直与内地相关单位保持紧密联系，并积 极协助内地当局的调研工作，亦参与商讨有关政策的制订及简化审批注册的要求。这项新措施将大大简 化评审要求及缩短审批时间，为有意开拓内地庞大市场的香港中药业界开辟更便捷的途径，进一步便利 香港中成药制造商开拓内地市场，推动中医药产业发展，亦是实现了香港特区行政长官2024年施政报告 下有关推动大湾区医疗协作的另一里程碑！要实现中华民族的伟大复兴，中国香港会继续发挥卓越医疗 卫生、中西文化汇萃、国际超级都会等各领域的优势，担当中医中药走向全球的桥头堡，做好超级联系 人的角色。" 智通财经APP获悉，4月28日，香港卫生署表示，会重锤夯基，加强宣传和推广，协助业界掌握在新安 排下申请人需要提交的资料和技术要求，让更多合资格的香港注册传统口服中成药早日顺利开拓内地市 场，并推动香港中医药产业发展。自简化港澳注册传统外用中成药注册审批流程于2021年实施至今，已 有13款香港注册传统外用中成药透过简化流程于内地上市。截至今日，香港注册中成药 ...